Novavax Company Profile (NASDAQ:NVAX)

About Novavax (NASDAQ:NVAX)

Novavax logoNovavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:NVAX
  • CUSIP: 67000210
  • Web: www.novavax.com
Capitalization:
  • Market Cap: $288.25 million
  • Outstanding Shares: 282,595,000
Average Prices:
  • 50 Day Moving Avg: $0.90
  • 200 Day Moving Avg: $1.24
  • 52 Week Range: $0.73 - $8.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.73
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $16.82 million
  • Price / Sales: 17.14
  • Book Value: ($0.10) per share
  • Price / Book: -10.20
Profitability:
  • EBIDTA: ($221,620,000.00)
  • Net Margins: -1,908.41%
  • Return on Equity: -189.14%
  • Return on Assets: -61.47%
Debt:
  • Debt-to-Equity Ratio: 6.35%
  • Current Ratio: 4.68%
  • Quick Ratio: 4.68%
Misc:
  • Average Volume: 6.55 million shs.
  • Beta: 1.72
  • Short Ratio: 8.61
 

Frequently Asked Questions for Novavax (NASDAQ:NVAX)

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) released its quarterly earnings results on Monday, May, 8th. The company reported ($0.16) EPS for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.02. The company had revenue of $5.68 million for the quarter, compared to analyst estimates of $6.17 million. Novavax had a negative return on equity of 189.14% and a negative net margin of 1,908.41%. Novavax's revenue was up 34.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.29) earnings per share. View Novavax's Earnings History.

Where is Novavax's stock going? Where will Novavax's stock price be in 2017?

9 brokerages have issued 1-year price objectives for Novavax's stock. Their predictions range from $1.00 to $25.00. On average, they anticipate Novavax's stock price to reach $5.71 in the next twelve months. View Analyst Ratings for Novavax.

What are analysts saying about Novavax stock?

Here are some recent quotes from research analysts about Novavax stock:

  • 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (3/3/2017)
  • 2. Chardan Capital analysts commented, "The company is at a pre-commercialization stage, although it does recognize revenue from research and development collaborations. Reported revenue in Q4 was $5.4M, which was inline with consensus." (2/28/2017)
  • 3. Cantor Fitzgerald analysts commented, "RSV maternal vaccination likely primary value driver in 2017. We believe investors will be keenly focused on the RSV vaccine when used in the context of maternal vaccination, particularly given the failure of the elderly subject RSV pivotal trial late last year. Clinical data suggest that the vaccine is immunogenic in pregnant women and that anti-RS F protein antibodies are efficiently transferred across the placenta to the fetus." (1/12/2017)
  • 4. Piper Jaffray Companies analysts commented, "So, Now What?" (9/16/2016)

Are investors shorting Novavax?

Novavax saw a increase in short interest in April. As of April 28th, there was short interest totalling 58,260,240 shares, an increase of 1.4% from the April 13th total of 59,113,432 shares. Based on an average trading volume of 4,519,366 shares, the days-to-cover ratio is presently 12.9 days. Currently, 21.7% of the shares of the stock are sold short.

Who are some of Novavax's key competitors?

Who owns Novavax stock?

Novavax's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.99%), FMR LLC (6.84%), State Street Corp (4.64%), BB Biotech AG (3.07%), JPMorgan Chase & Co. (1.37%) and Morgan Stanley (1.16%). Company insiders that own Novavax stock include Barclay A Phillips, Gail Boudreaux, Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rajiv I Modi and Stanley C Erck. View Institutional Ownership Trends for Novavax.

Who sold Novavax stock? Who is selling Novavax stock?

Novavax's stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, FMR LLC, Creative Planning, Morgan Stanley, TIAA CREF Investment Management LLC, Schwab Charles Investment Management Inc., Renaissance Technologies LLC and Bank of America Corp DE. View Insider Buying and Selling for Novavax.

Who bought Novavax stock? Who is buying Novavax stock?

Novavax's stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Vanguard Group Inc., Credit Suisse AG, Geode Capital Management LLC, Goldman Sachs Group Inc., Canada Pension Plan Investment Board, KCG Holdings Inc. and American International Group Inc.. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax.

How do I buy Novavax stock?

Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Novavax stock cost?

One share of Novavax stock can currently be purchased for approximately $1.02.

Analyst Ratings

Consensus Ratings for Novavax (NASDAQ:NVAX) (?)
Ratings Breakdown: 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.22)
Consensus Price Target: $5.71 (459.68% upside)

Analysts' Ratings History for Novavax (NASDAQ:NVAX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/8/2017Cantor FitzgeraldSet Price TargetHold$2.00HighView Rating Details
3/1/2017Ladenburg Thalmann Financial ServicesReiterated RatingNeutralN/AView Rating Details
2/28/2017Chardan CapitalReiterated RatingHold$1.50N/AView Rating Details
1/18/2017FBR & CoReiterated RatingOutperform$12.00N/AView Rating Details
11/11/2016WedbushReiterated RatingNeutral$2.00 -> $1.50N/AView Rating Details
11/10/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
9/16/2016S&P Equity ResearchLower Price Target$1.44 -> $1.17N/AView Rating Details
9/16/2016Citigroup IncDowngradeBuy -> Neutral$12.00 -> $1.50N/AView Rating Details
9/16/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$14.00 -> $1.00N/AView Rating Details
8/29/2016GuggenheimReiterated RatingBuy$25.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Novavax (NASDAQ:NVAX)
Earnings by Quarter for Novavax (NASDAQ:NVAX)
Earnings History by Quarter for Novavax (NASDAQ:NVAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.18)($0.16)$6.17 million$5.68 millionViewListenView Earnings Details
2/27/2017Q416($0.23)($0.21)$5.45 million$5.40 millionViewListenView Earnings Details
11/9/2016Q316($0.26)($0.24)$4.02 million$3.20 millionViewListenView Earnings Details
8/9/2016Q216($0.25)($0.29)$8.03 million$2.50 millionViewListenView Earnings Details
5/4/2016Q1($0.27)($0.29)$10.39 million$4.20 millionViewListenView Earnings Details
2/29/2016Q415($0.14)($0.29)$8.07 million$5.90 millionViewListenView Earnings Details
11/9/2015Q315($0.09)($0.12)$10.59 million$6.50 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)($0.08)$9.90 million$14.00 millionViewListenView Earnings Details
5/7/2015Q115($0.11)($0.10)$9.70 million$9.88 millionViewN/AView Earnings Details
2/26/2015Q4 14($0.08)($0.13)$9.60 million$6.70 millionViewN/AView Earnings Details
11/5/2014Q314($0.07)($0.08)$9.20 million$8.20 millionViewN/AView Earnings Details
8/6/2014Q214($0.07)($0.08)$8.74 million$8.26 millionViewN/AView Earnings Details
5/7/2014Q114($0.07)($0.07)$3.80 million$7.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.08)($0.07)$6.22 million$8.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.06)($0.09)$4.56 million$4.80 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.06)($0.08)$4.45 million$3.50 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.06)($0.07)$5.54 million$3.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.04)($0.06)$5.85 million$4.57 millionViewN/AView Earnings Details
11/2/2012Q312($0.05)($0.05)$7.59 million$5.80 millionViewN/AView Earnings Details
8/3/2012($0.07)($0.05)ViewN/AView Earnings Details
5/4/2012($0.04)($0.06)ViewN/AView Earnings Details
3/9/2012($0.04)($0.03)ViewN/AView Earnings Details
11/4/2011($0.06)($0.03)ViewN/AView Earnings Details
8/5/2011($0.08)($0.04)ViewN/AView Earnings Details
5/9/2011($0.07)($0.07)ViewN/AView Earnings Details
3/28/2011($0.09)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novavax (NASDAQ:NVAX)
2017 EPS Consensus Estimate: ($0.64)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.19)($0.17)($0.18)
Q2 20172($0.16)($0.15)($0.16)
Q3 20172($0.17)($0.15)($0.16)
Q4 20172($0.15)($0.14)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Novavax (NASDAQ:NVAX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Novavax (NASDAQ:NVAX)
Insider Ownership Percentage: 3.50%
Institutional Ownership Percentage: 60.36%
Insider Trades by Quarter for Novavax (NASDAQ:NVAX)
Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)
Insider Trades by Quarter for Novavax (NASDAQ:NVAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Michael A Mcmanus JrDirectorBuy20,000$0.97$19,400.00View SEC Filing  
5/11/2017Barclay A PhillipsCFOBuy25,000$0.84$21,000.00View SEC Filing  
5/11/2017Michael A Mcmanus JrDirectorBuy10,000$0.84$8,400.00View SEC Filing  
5/11/2017Stanley C ErckInsiderBuy50,000$0.84$42,000.00View SEC Filing  
1/31/2017Barclay A. PhillipsCFOBuy1,633$1.12$1,828.96View SEC Filing  
1/31/2017John A. Herrmann IIISVPBuy4,960$1.12$5,555.20View SEC Filing  
12/7/2016Gregory M GlennInsiderBuy1,000$1.45$1,450.00View SEC Filing  
9/22/2016John TrizzinoSVPBuy46,000$2.17$99,820.00View SEC Filing  
9/21/2016Gregory M GlennInsiderBuy1,000$1.65$1,650.00View SEC Filing  
9/21/2016Michael A Mcmanus JrDirectorBuy30,000$1.61$48,300.00View SEC Filing  
9/20/2016Gail BoudreauxDirectorBuy100,000$1.45$145,000.00View SEC Filing  
7/31/2016Barclay A. PhillipsCFOBuy422$4.29$1,810.38View SEC Filing  
6/6/2016Gary C EvansDirectorSell18,998$6.50$123,487.00View SEC Filing  
5/24/2016Gary C EvansDirectorSell50,000$5.41$270,500.00View SEC Filing  
3/31/2016Stanley C ErckCEOSell424,778$5.19$2,204,597.82View SEC Filing  
1/31/2016Barclay A. PhillipsCFOBuy405$4.38$1,773.90View SEC Filing  
1/31/2016Gregory M. GlennSVPBuy2,369$4.38$10,376.22View SEC Filing  
1/31/2016Stanley C. ErckCEOBuy2,072$4.38$9,075.36View SEC Filing  
12/16/2015John A Herrmann IIISVPSell27,945$8.64$241,444.80View SEC Filing  
8/24/2015Gary C EvansDirectorSell20,000$11.24$224,800.00View SEC Filing  
8/20/2015Barclay A. PhillipsCFOSell28,656$13.06$374,247.36View SEC Filing  
8/18/2015Gregory M. GlennSVPSell15,000$13.52$202,800.00View SEC Filing  
8/13/2015Gary C EvansDirectorSell6,002$13.56$81,387.12View SEC Filing  
6/18/2015James F YoungDirectorSell50,000$9.47$473,500.00View SEC Filing  
6/17/2015Rajiv I ModiDirectorSell433,053$9.01$3,901,807.53View SEC Filing  
6/11/2015Rajiv I ModiDirectorSell11,185$9.00$100,665.00View SEC Filing  
6/10/2015Rajiv I ModiDirectorSell551,081$8.97$4,943,196.57View SEC Filing  
6/9/2015Rajiv I ModiDirectorSell47,531$8.93$424,451.83View SEC Filing  
6/8/2015Rajiv I ModiDirectorSell206,175$8.93$1,841,142.75View SEC Filing  
6/4/2015Rajiv I ModiDirectorSell504,681$8.92$4,501,754.52View SEC Filing  
6/1/2015Rajiv I ModiDirectorSell3,500,000$8.74$30,590,000.00View SEC Filing  
1/31/2015Barclay A PhillipsCFOBuy8,388$2.28$19,124.64View SEC Filing  
1/31/2015John TrizzinoSVPBuy6,611$3.63$23,997.93View SEC Filing  
1/31/2015Stanley C ErckCEOBuy6,122$2.28$13,958.16View SEC Filing  
12/16/2014Gary C EvansDirectorSell46,701$5.72$267,129.72View SEC Filing  
12/12/2014Gary C EvansDirectorSell30,000$5.77$173,100.00View SEC Filing  
11/20/2014Rajiv I ModiDirectorSell518,889$5.02$2,604,822.78View SEC Filing  
11/18/2014Rajiv I ModiDirectorSell1,481,111$5.00$7,405,555.00View SEC Filing  
10/3/2014Barclay A PhillipsCFOBuy5,000$4.11$20,550.00View SEC Filing  
10/3/2014Timothy Jon HahnSVPBuy2,500$4.05$10,125.00View SEC Filing  
9/26/2014Gregory M GlennSVPSell16,809$4.16$69,925.44View SEC Filing  
9/25/2014Timothy Jon HahnSVPBuy9,000$4.17$37,530.00View SEC Filing  
7/31/2014Barclay A PhillipsCFOBuy8,788$2.28$20,036.64View SEC Filing  
7/31/2014Russell P WilsonSVPBuy4,989$2.28$11,374.92View SEC Filing  
7/31/2014Stanley C ErckCEOBuy6,788$2.28$15,476.64View SEC Filing  
6/17/2014John TrizzinoSVPBuy5,500$4.51$24,805.00View SEC Filing  
6/16/2014John TrizzinoSVPBuy16,500$4.51$74,415.00View SEC Filing  
3/25/2014Barclay PhillipsCFOBuy5,000$4.25$21,250.00View SEC Filing  
3/25/2014Richard DouglasDirectorBuy50,000$4.33$216,500.00View SEC Filing  
3/25/2014Stanley ErckCEOBuy10,000$4.27$42,700.00View SEC Filing  
3/21/2014Pharmaceuticals Ltd Cadilamajor shareholderSell3,000,000$4.95$14,850,000.00View SEC Filing  
1/31/2014Barclay PhillipsCFOBuy9,868$2.29$22,597.72View SEC Filing  
1/31/2014Stanley ErckCEOBuy11,868$2.29$27,177.72View SEC Filing  
1/31/2014Timothy Jon HahnSVPBuy9,416$2.29$21,562.64View SEC Filing  
6/12/2013Richard DouglasDirectorBuy50,000$1.90$95,000.00View SEC Filing  
6/10/2013Timothy Jon HahnSVPBuy21,000$1.88$39,480.00View SEC Filing  
6/7/2013Gregory M GlennInsiderBuy2,000$1.92$3,840.00View SEC Filing  
6/6/2013James F YoungDirectorBuy100,000$1.91$191,000.00View SEC Filing  
3/11/2013James F YoungDirectorBuy100,000$2.03$203,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Novavax (NASDAQ:NVAX)
Latest Headlines for Novavax (NASDAQ:NVAX)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Novavax, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 6:09 PM
finance.yahoo.com logoNovavax Financial Review, Analysts Target and Outlook
finance.yahoo.com - May 19 at 11:41 AM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Novavax and Progenics Pharmaceuticals
finance.yahoo.com - May 19 at 11:41 AM
americanbankingnews.com logo$5.81 Million in Sales Expected for Novavax, Inc. (NVAX) This Quarter
www.americanbankingnews.com - May 17 at 9:10 AM
finance.yahoo.com logoNovavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : May 16, 2017
finance.yahoo.com - May 16 at 10:07 AM
finance.yahoo.com logoBiotech Movers: Akebia, Editas, Novavax
finance.yahoo.com - May 16 at 10:07 AM
americanbankingnews.com logoNovavax, Inc. (NVAX) Expected to Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - May 16 at 12:24 AM
finance.yahoo.com logoHere's What's Driving Up Novavax, Inc. Stock Again Today
finance.yahoo.com - May 15 at 6:16 PM
fool.com logoHere's What's Driving Up Novavax, Inc. Stock Again Today
www.fool.com - May 15 at 1:25 PM
fool.com logoHere's What Is Pushing Up Novavax, Inc. Stock Today - Motley Fool
www.fool.com - May 13 at 8:21 AM
americanbankingnews.com logoNovavax, Inc. (NVAX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - May 12 at 7:00 PM
americanbankingnews.com logoInsider Buying: Novavax, Inc. (NVAX) Director Acquires 20,000 Shares of Stock
www.americanbankingnews.com - May 12 at 4:46 PM
americanbankingnews.com logoFY2017 EPS Estimates for Novavax, Inc. Boosted by Analyst (NVAX)
www.americanbankingnews.com - May 12 at 12:32 PM
finance.yahoo.com logoHere's What Is Pushing Up Novavax, Inc. Stock Today
finance.yahoo.com - May 11 at 7:23 PM
finance.yahoo.com logoETFs with exposure to Novavax, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 7:23 PM
fool.com logoHere's What Is Pushing Up Novavax, Inc. Stock Today
www.fool.com - May 11 at 5:35 PM
americanbankingnews.com logoBarclay A. Phillips Purchases 25,000 Shares of Novavax, Inc. (NVAX) Stock
www.americanbankingnews.com - May 11 at 1:38 PM
americanbankingnews.com logoStanley C. Erck Buys 50,000 Shares of Novavax, Inc. (NVAX) Stock
www.americanbankingnews.com - May 11 at 1:16 PM
finance.yahoo.com logoNovavax Announces the Promotion of Dr. James F. Cummings to Vice President, Clinical Development and Translational Medicine
finance.yahoo.com - May 11 at 9:12 AM
finance.yahoo.com logoNovavax, Inc. :NVAX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 11:58 AM
finance.yahoo.com logoNovavax, Inc Is Rising Today, but You Should Still Stay Far Away
finance.yahoo.com - May 9 at 6:33 PM
finance.yahoo.com logoNovavax shares jump on news of narrowed first-quarter losses
finance.yahoo.com - May 9 at 6:33 PM
americanbankingnews.com logoCantor Fitzgerald Analysts Give Novavax, Inc. (NVAX) a $2.00 Price Target
www.americanbankingnews.com - May 9 at 2:34 PM
finance.yahoo.com logoEdited Transcript of NVAX earnings conference call or presentation 8-May-17 8:30pm GMT
finance.yahoo.com - May 9 at 11:25 AM
americanbankingnews.com logoNovavax, Inc. (NVAX) Releases Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 8 at 9:24 PM
rttnews.com logoEARNINGS SUMMARY: Details of Novavax Inc. Q1 Earnings Report
www.rttnews.com - May 8 at 6:23 PM
finance.yahoo.com logoNovavax Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 6:23 PM
marketbeat.com logoNovavax reports 1Q loss
marketbeat.com - May 8 at 4:53 PM
finance.yahoo.com logoInvestor Network: Novavax, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 12:16 PM
americanbankingnews.com logoNovavax (NVAX) Given Daily Coverage Optimism Score of 0.14
www.americanbankingnews.com - May 5 at 11:21 PM
americanbankingnews.com logoNovavax (NVAX) Receiving Somewhat Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - May 2 at 8:44 PM
finance.yahoo.com logoNovavax to Host Conference Call to Discuss First Quarter 2017 Financial ...
finance.yahoo.com - May 1 at 5:52 PM
finance.yahoo.com logoETFs with exposure to Novavax, Inc. : May 1, 2017
finance.yahoo.com - May 1 at 5:52 PM
finance.yahoo.com logoNo bonuses for Novavax following failed RSV vaccine trial
finance.yahoo.com - May 1 at 5:52 PM
finance.yahoo.com logoNovavax to Host Conference Call to Discuss First Quarter 2017 Financial Results on May 8, 2017
finance.yahoo.com - May 1 at 12:12 PM
feeds.benzinga.com logoNovavax to Host Conference Call to Discuss First Quarter 2017 Financial Results on May 8, 2017
feeds.benzinga.com - May 1 at 11:31 AM
seekingalpha.com logoNovavax: If Only
seekingalpha.com - April 28 at 7:57 PM
americanbankingnews.com logoNovavax (NVAX) Receiving Somewhat Critical Media Coverage, Report Shows
www.americanbankingnews.com - April 28 at 12:38 PM
americanbankingnews.com logoNovavax (NVAX) Receives Media Sentiment Rating of 0.10
www.americanbankingnews.com - April 25 at 5:00 PM
finance.yahoo.com logoETFs with exposure to Novavax, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 6:58 PM
americanbankingnews.com logoNovavax, Inc. (NVAX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 17 at 6:58 PM
americanbankingnews.com logoNovavax (NVAX) Getting Somewhat Negative Press Coverage, Report Shows
www.americanbankingnews.com - April 15 at 1:21 PM
americanbankingnews.com logoNovavax, Inc. (NVAX) Sees Large Decline in Short Interest
www.americanbankingnews.com - April 14 at 7:24 AM
finance.yahoo.com logoBiotech Movers Trading Positive Ahead of Market's Open
finance.yahoo.com - April 11 at 10:52 AM
finance.yahoo.com logoETFs with exposure to Novavax, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 7:20 PM
finance.yahoo.com logoImplied Volatility Surging for Novavax (NVAX) Stock Options
finance.yahoo.com - April 7 at 11:35 AM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Sarepta Therapeutics and Novavax
finance.yahoo.com - April 7 at 11:35 AM
fool.com logoDown 12.5%: Is Novavax Stock Too Cheap To Ignore?
www.fool.com - April 7 at 9:51 AM
fool.com logoThe Waiting Game Crushed Novavax, Inc. in March, Sending Shares Down 15%
www.fool.com - April 5 at 11:16 AM
seekingalpha.com logoVBI Vaccines Is An Alternative To The Agenus Inc. Failure
seekingalpha.com - March 28 at 10:02 AM

Social

Chart

Novavax (NVAX) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff